Skip to content
AnalystLens

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (May 4, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed May 4, 2026
Period End
May 4, 2026
Security
VRTX
In the record · 2016–202610-K1110-Q328-K100

VRTX filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 100 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Oct ’17Oct ’17
  2. Leadership change8-K · Apr ’20Apr ’20
  3. Material agreement8-K · Jul ’22Jul ’22
  4. Leadership change8-K · Feb ’25Feb ’25

01—Abstract

Summary

Summary of the 8-K filed May 4, 2026. Cited figures are marked; the original filing is the authoritative source.

Vertex Pharmaceuticals reported first quarter 2026 results on May 4, 2026, with total revenue of $2.99 billiona, up 8% year over year, driven by cystic fibrosis (CF) franchise performance and early contributions from CASGEVY and JOURNAVX.

GAAP net income rose to $1.03 billionb from $646 million, though the prior-year period carried a $379 million intangible impairment. Non-GAAP diluted EPS was $4.47 versus $4.06 a year earlier. CF product revenue was $2.92 billion, with ALYFTREK ($424 million, up from $54 million) increasingly offsetting a 7% decline in TRIKAFTA/KAFTRIO to $2.35 billion as the mix shifts to the newer product.

Management reiterated full-year 2026 guidance of $12.95c–13.1 billion in total revenue and at least $500 million in non-CF product revenue. Expenses rose modestly, with non-GAAP R&D, acquired IPR&D and SG&A at $1.29 billion versus $1.23 billion, reflecting JOURNAVX launch spending and build-out of the renal franchise led by povetacicept in IgA nephropathy. Cash and marketable securities reached $13.0 billion, up from $12.3 billion at year-end 2025, supported by operating cash flow and partly offset by share repurchases.

The company completed the rolling BLA submission for povetacicept in IgAN under a Priority Review Voucher, which implies a six-month FDA review from acceptance, and it discontinued the VX-522 cystic fibrosis gene-editing program after persistent tolerability issues. For investors, the key questions are the durability of TRIKAFTA's decline against ALYFTREK's ramp, the pace of non-CF revenue growth needed to hit guidance, and regulatory timing for povetacicept and the CASGEVY pediatric submission. The filing is an Item 2.02 earnings release furnished under Exhibit 99.1, so its content is not subject to Section 18 liability.

02—Key points

Key Highlights

  1. Total revenue of $2.99 billion, up 8% year over year; U.S. revenue rose 7% to $1.78 billion and ex-U.S. revenue rose 9% to $1.21 billion.
  2. ALYFTREK revenue of $424 million versus $54 million a year earlier, while TRIKAFTA/KAFTRIO declined to $2.35 billion from $2.54 billion.
  3. GAAP net income of $1.03 billion ($4.02 diluted EPS) versus $646 million in Q1 2025, which included a $379 million impairment; non-GAAP EPS was $4.47 versus $4.06.
  4. CASGEVY revenue of $43 million (versus $14 million) and JOURNAVX revenue of $29 million (versus $1 million), together contributing more than 25% of the quarter's growth.
  5. FY 2026 guidance reiterated: total revenue of $12.95–13.1 billion, non-CF product revenue of at least $500 million, and non-GAAP R&D/AIPR&D/SG&A of $5.65–5.75 billion.
  6. Povetacicept completed its rolling BLA for accelerated approval in IgAN, using a Priority Review Voucher for a six-month review after FDA acceptance; the company also started the Phase 3 portion of the pMN study.
  7. Cash and marketable securities rose to $13.0 billion from $12.3 billion at year-end 2025, while the company continued share repurchases; VX-522 development was discontinued due to tolerability issues.

03—Questions

Frequently Asked Questions

  1. How did Vertex perform in Q1 2026 versus Q1 2025?

    Total revenue rose 8% to $2.99 billion. GAAP net income more than doubled to $1.03 billion from $646 million, but the comparison is flattered by a $379 million impairment charge in Q1 2025. Non-GAAP net income rose $93 million to $1.15 billion (the release text cites $1.1 billion).

  2. Is Vertex still on track for its 2026 guidance?

    Yes. Management reiterated full-year 2026 guidance of $12.95–13.1 billion in total revenue and at least $500 million in non-CF product revenue, and left the expense and non-GAAP tax rate ranges unchanged. Q1 results alone represent roughly 23% of the revenue midpoint.

  3. What is the outlook for povetacicept and the renal franchise?

    Vertex completed the rolling BLA submission for accelerated approval in IgA nephropathy, using a Priority Review Voucher that targets a six-month FDA review after acceptance. It has also started the Phase 3 portion of the OLYMPUS study in primary membranous nephropathy and a Phase 2 study in generalized myasthenia gravis. Renal spending is a key driver of higher operating expenses.

  4. Does the decline in TRIKAFTA/KAFTRIO threaten growth?

    TRIKAFTA/KAFTRIO fell about 7% to $2.35 billion, but ALYFTREK's rapid uptake ($424 million) more than offset the decline, and total CF product revenue grew 6% to $2.92 billion. Expanded U.S. label coverage for ALYFTREK and TRIKAFTA, covering about 95% of U.S. CF patients, supports continued CF growth.

04—Continue

← View all 8-K filings